Mayne Pharma 2025 Full Year Results Media Release
Mayne Pharma’s CEO, Mr Shawn Patrick O’Brien said “Overall, the performance of the business in FY25 generated significant underlying EBITDA growth, reflecting revenue growth with modest increases in our operating costs. Our Women’s Health business continued to benefit from our targeted sales, marketing and education initiatives and effective channel management. For Dermatology, we look forward to the impact of the US market launches of our newly acquired products EPSOLAY® and TWYNEO® in FY26 (launched during this current quarter) and continued growth from Adelaide Apothecary, which achieved EBITDA break even in FY25.”
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Mayne Pharma Group Limited a question about this update.